[Treatment of DIC associated with myelogenous leukemia].
Many hematologists believe that anti-tumor drugs and platelet transfusion are enough for the treatment of disseminated intravascular coagulation (DIC) associated with myelogenous leukemia. In this paper, showing the pathophysiology of 3 types of DIC, I insisted the necessity of anticoagulant therapy to avoid the bleeding death or ischemic organ damage before achieving the hematological remission, because myelogenous leukemia is now a curable disease. In addition, I introduced the new Japan-made weapon to DIC, recombinant thrombomodulin, which complexes with thrombin and regulates the coagulation activity by efficient activation of protein C. Using two different natural anticoagulant systems, antithrombin and protein C pathway, we can more effectively improve DIC treatment and alleviate symptoms in DIC patients.
Sakata
Yoichi
Y
Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University School of Medicine.
D000925:Anticoagulants / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000145:classification / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D016670:Gabexate / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications*; D017713:Platelet Transfusion; D011486:Protein C; D011994:Recombinant Proteins / Q000627:therapeutic use; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use; D018180:Thrombomodulin / Q000627:therapeutic use*
D000925:Anticoagulants; D011486:Protein C; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; D018180:Thrombomodulin; D016670:Gabexate; D006493:Heparin